bntx - Search News

News

GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over mRNA vaccine patents. Read more here.

Yahoo Finance · 1d

BioNTech (BNTX) Settles mRNA Patent Dispute with CureVac for US$370 Million

Recent developments have highlighted a major mRNA patent settlement involving BioNTech (BNTX) and CureVac, leading to a $370 million payment with GSK plc, which has added complexity to BioNTech's financial landscape.

TipRanks on MSN · 1d

GSK provides update on U.S. settlement CureVac/BioNTech mRNA patent litigation

GSK (GSK) announces that, in connection with the mRNA patent settlement reached between CureVac (CVAC) and BioNTech on 7 August 2025, the Company

The Financial Times · 1d

BioNTech settles Covid-19 patent dispute with CureVac

BioNTech has agreed to pay UK drugmaker GSK royalties on its Covid-19 and influenza vaccines as part of a patent settlement with CureVac, in a deal that allows the biotech to move forward with the purchase of its German rival.

Barron's · 1d

Pfizer, BioNTech Reach Covid Jab Settlement With GSK, CureVac

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac $740 million plus royalties to settle US legal disputes over Covid-19 vaccines, CureVac said Friday.

BioNTech SE (NASDAQ:BNTX) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

It's been a good week for BioNTech SE (NASDAQ:BNTX) shareholders, because the company has just released its latest quarterly results, and the shares gained 3.6% to US$111. It was a moderately negative ...

TipRanks on MSN2d

BioNTech and Genmab’s GEN1056 Study: A New Hope for Advanced Tumor Treatment

The intervention under investigation is GEN1056, a biological treatment administered via intravenous infusion. Its primary purpose is to evaluate safety and antitumor activity, with the ultimate goal ...

These Analysts Revise Their Forecasts On BioNTech After Q2 Results

BioNTech reaffirmed its fiscal year 2025 guidance of 1.7 billion-2.2 billion euros compared to the consensus of 2.05 billion ...

BioNTech SE (BNTX) Gets a Buy from Evercore ISI

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Morningstar5d

BNTX - BioNTech SE ADR Dividends | Morningstar

Review the current BioNTech SE ADR (BNTX:XNAS) dividend yield and history to decide if BNTX is the best investment for you.

5don MSN

BioNTech posts Q2 beat as revenue more than doubles

ADRs added ~2% in the premarket on Monday after the German vaccine maker exceeded Street forecasts with its Q2 2025 ...

Goldman Sachs Sticks to Its Hold Rating for BioNTech SE (BNTX)

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

BioNTech SE (BNTX) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ...

BioNTech SE (BNTX) reports significant revenue growth and strategic advancements despite ongoing challenges in the COVID-19 ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results